Compare ASIC & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ASIC | XERS |
|---|---|---|
| Founded | 2018 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 2025 | 2018 |
| Metric | ASIC | XERS |
|---|---|---|
| Price | $18.20 | $7.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $25.25 | $10.43 |
| AVG Volume (30 Days) | 79.4K | ★ 2.5M |
| Earning Date | 02-23-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 504.00 | N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $405,657,000.00 | $266,137,000.00 |
| Revenue This Year | $14.87 | $44.37 |
| Revenue Next Year | $44.91 | $27.87 |
| P/E Ratio | $104.08 | ★ N/A |
| Revenue Growth | ★ 68.10 | 42.05 |
| 52 Week Low | $16.35 | $3.15 |
| 52 Week High | $25.30 | $10.08 |
| Indicator | ASIC | XERS |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 50.93 |
| Support Level | N/A | $7.37 |
| Resistance Level | N/A | $8.42 |
| Average True Range (ATR) | 0.00 | 0.42 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 0.00 | 39.13 |
Ategrity Specialty Insurance Co Holdings Formerly Ategrity Specialty Holdings LLC is a specialty insurance company dedicated to providing excess and surplus products to small to medium-sized businesses across the United States. It offers property and casualty insurance solutions tailored to meet the needs of SMBs. The company focuses on are Real Estate, Hospitality, Construction, and Retail.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).